膜杰作
Star Staining
抗体来源（Source）
Anti-Cetuximab Antibody (12B1E9) (CEB-Y29c) is a monoclonal antibody recombinantly expressed from human 293 cells (HEK293). The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab ADA.
亚型（Isotype）
Mouse IgG1/kappa
特异性（Specificity）
Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Anti-Cetuximab Antibody (12B1E9) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Anti-Cetuximab Antibody (12B1E9) (Cat. No. CEB-Y29c) is more than 90% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized Cetuximab at 1 μg/mL (100 μL/well) can bind Anti-Cetuximab Antibody (12B1E9) (Cat. No. CEB-Y29c) with a linear range of 0.2-1.6 ng/mL (QC tested).
Protocol
背景（Background）
Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.
